Search

Displaying results 4401 - 4410 of 8974 in total
  1. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

  2. Drug

    Sodium bisulfite

    go.drugbank.com/drugs/DB14015
    ApprovedWithdrawn

    Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Cilostazol

    go.drugbank.com/drugs/DB01166
    ApprovedInvestigational

    It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  5. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. … Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources.

    Synonyms: Viral Specific T-lymphocytes, HLA-matched Virus Specific T Cells
  6. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

  7. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  8. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  9. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: Mixture of Four Standardized Grasses, K-O-T Standardized Grass Pollen MixProducts: GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT 100 TABLET, GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT TABLET, 30 ADET
  10. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis … Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.